Comparison

KPV vs. TB-500

Two peptides side-by-side — identity, evidence base, legal status and known adverse events.

Identity

Mechanism of action

KPV

KPV is the C-terminal fragment of α-melanocyte-stimulating hormone (α-MSH). In preclinical models the inflammation-modulating activity is attributed predominantly to inhibition of the NF-κB and MAP-kinase signalling pathways, accompanied by reduced release of pro-inflammatory mediators. Cellular uptake via the peptide transporter PepT1 has also been described. The precise molecular mechanisms are not conclusively understood and not confirmed in humans.

TB-500

Synthetic fragment of the endogenous protein Thymosin Beta-4. In preclinical models, an influence on cell migration, actin sequestration and neovascularisation has been described. Robust human pharmacokinetic data are not publicly available.

Evidence base

Highest evidence

Animal model

Studies

of which in humans

Effects recorded

Open conflicts

Documented adverse events

Legal status

Country	KPV	TB-500
Australia	—	Banned
Germany	Unapproved	Unapproved
United States	Research only	Research only

Full entries

Frequently asked questions

What is the difference between KPV and TB-500?: KPV is classified as "Healing", while TB-500 is classified as "Healing". KPV: KPV is the C-terminal tripeptide (lysine-proline-valine) of the hormone α-MSH, corresponding to its positions 11–13. In cell and rodent models an inflammation-modulating activity has been described, primarily via inhibition of the NF-κB signalling pathway. The evidence is drawn almost exclusively from preclinical work (cell culture and mouse); controlled human studies are essentially absent. KPV is not an approved medicinal product. TB-500: Synthetic fragment of the endogenous protein Thymosin Beta-4, specifically the actin-binding sequence. Preclinical models investigate effects on cell migration, neovascularisation and wound healing — robust human data are absent. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, KPV or TB-500?: The highest available evidence level is "Animal model" for KPV and "Animal model" for TB-500. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of KPV and TB-500 in Germany and the United States?: Germany: KPV — Unapproved, TB-500 — Unapproved. United States: KPV — Research only, TB-500 — Research only. These are factual summaries with source and review date on the individual pages.

Country

KPV

TB-500

Australia

—

Banned

Germany

Unapproved

United States

Research only

Frequently asked questions

What is the difference between KPV and TB-500?

KPV is classified as "Healing", while TB-500 is classified as "Healing". KPV: KPV is the C-terminal tripeptide (lysine-proline-valine) of the hormone α-MSH, corresponding to its positions 11–13. In cell and rodent models an inflammation-modulating activity has been described, primarily via inhibition of the NF-κB signalling pathway. The evidence is drawn almost exclusively from preclinical work (cell culture and mouse); controlled human studies are essentially absent. KPV is not an approved medicinal product. TB-500: Synthetic fragment of the endogenous protein Thymosin Beta-4, specifically the actin-binding sequence. Preclinical models investigate effects on cell migration, neovascularisation and wound healing — robust human data are absent. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, KPV or TB-500?

The highest available evidence level is "Animal model" for KPV and "Animal model" for TB-500. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of KPV and TB-500 in Germany and the United States?

Germany: KPV — Unapproved, TB-500 — Unapproved. United States: KPV — Research only, TB-500 — Research only. These are factual summaries with source and review date on the individual pages.